Next Biomedical Co.,Ltd. (KOSDAQ:389650)

Next Biomedical Statistics

Total Valuation

Next Biomedical has a market cap or net worth of KRW 645.65 billion. The enterprise value is 626.47 billion.

Market Cap	645.65B
Enterprise Value	626.47B

Important Dates

The next estimated earnings date is Friday, March 13, 2026.

Earnings Date	Mar 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Next Biomedical has 8.20 million shares outstanding. The number of shares has increased by 19.72% in one year.

Current Share Class	8.20M
Shares Outstanding	8.20M
Shares Change (YoY)	+19.72%
Shares Change (QoQ)	+0.14%
Owned by Insiders (%)	31.75%
Owned by Institutions (%)	9.16%
Float	5.12M

Valuation Ratios

PE Ratio	n/a
Forward PE	225.55
PS Ratio	43.32
PB Ratio	13.96
P/TBV Ratio	14.06
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-5,318.98
EV / Sales	42.03
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-153.42

Financial Position

The company has a current ratio of 3.64, with a Debt / Equity ratio of 0.18.

Current Ratio	3.64
Quick Ratio	3.29
Debt / Equity	0.18
Debt / EBITDA	n/a
Debt / FCF	-2.02
Interest Coverage	-3.30

Financial Efficiency

Return on equity (ROE) is -0.26% and return on invested capital (ROIC) is -1.58%.

Return on Equity (ROE)	-0.26%
Return on Assets (ROA)	-1.49%
Return on Invested Capital (ROIC)	-1.58%
Return on Capital Employed (ROCE)	-2.86%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.26
Inventory Turnover	1.79

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +82.41% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+82.41%
50-Day Moving Average	80,328.00
200-Day Moving Average	59,631.25
Relative Strength Index (RSI)	41.43
Average Volume (20 Days)	125,023

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Next Biomedical had revenue of KRW 14.90 billion and -117.78 million in losses. Loss per share was -606.21.

Revenue	14.90B
Gross Profit	10.09B
Operating Income	-1.39B
Pretax Income	-117.78M
Net Income	-117.78M
EBITDA	-869.58M
EBIT	-1.39B
Loss Per Share	-606.21

Balance Sheet

The company has 27.42 billion in cash and 8.24 billion in debt, with a net cash position of 19.18 billion or 2,337.44 per share.

Cash & Cash Equivalents	27.42B
Total Debt	8.24B
Net Cash	19.18B
Net Cash Per Share	2,337.44
Equity (Book Value)	46.25B
Book Value Per Share	5,690.66
Working Capital	25.09B

Cash Flow

In the last 12 months, operating cash flow was -991.59 million and capital expenditures -3.09 billion, giving a free cash flow of -4.08 billion.

Operating Cash Flow	-991.59M
Capital Expenditures	-3.09B
Free Cash Flow	-4.08B
FCF Per Share	-497.72

Margins

Gross margin is 67.67%, with operating and profit margins of -9.33% and -0.79%.

Gross Margin	67.67%
Operating Margin	-9.33%
Pretax Margin	-0.79%
Profit Margin	-0.79%
EBITDA Margin	-5.83%
EBIT Margin	-9.33%
FCF Margin	n/a

Dividends & Yields

Next Biomedical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-19.72%
Shareholder Yield	-19.72%
Earnings Yield	-0.02%
FCF Yield	-0.63%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Next Biomedical has an Altman Z-Score of 18.33 and a Piotroski F-Score of 2.

Altman Z-Score	18.33
Piotroski F-Score	2